First granted ICOone® patent in India
Iconovo AB (publ) has been granted its first patent in India on the inhalation platform ICOone®. Iconovo has previously granted ICOone® patents in Europe (EPO) and have several patents pending in USA, India, China and Japan.
Abbreviated interim report january – december 2020
50 percent growth in 2020 and ambitious goals for the future
In search for vaccinations without cold storage – CTO Orest Lastow in MEDTECH Outlook
After an unprecedented year in the covid-19 pandemic, the challenges with vaccines requiring cold storage, from refrigeration to ultra-cold storage has become public knowledge. Dr Orest Lastow, founder and CTO of Iconovo AB (publ) that develops complete inhalation products, shares his thinking about a better vaccine solution in MEDTECH Outlook – to inhale a stable dry powder formulation using a single-use inhaler like ICOone from Iconovo.
Second ICOres® patent granted in the United States
United States Patent and Trademark Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device, ICOres.
Dr. Kyrre Thalberg new Senior Advisor in formulation development
Iconovo AB (publ) has appointed dr. Kyrre Thalberg to be Senior Advisor in formulation development.
The first two ICOpre® patents filed
Iconovo AB (publ) has filed two ICOpre® patent applications.
Iconovo signs agreement for development of inhaled oxytocin in ICOone for maternal health
Lund, December 21, 2020. Iconovo AB (publ) today announced that the company has signed a development agreement with Monash University for the development of inhaled oxytocin in ICOone®. The agreement verifies the suitability of ICOone for use with innovative pharmaceuticals. Monash University’s Institute of Pharmaceutical Sciences (MIPS) is leading the development project supported by a research agreement with Janssen Pharmaceutica N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and ongoing support from long term partner GSK.
US FDA Type III Drug Master File submitted for capsule inhaler ICOcap® from Iconovo
Iconovo announce that the capsule-based dry powder inhaler ICOcap® has been submitted to U.S. Food and Drug Administration (FDA) by partner Stevanato…
Nomination Committee appointed at Iconovo
At the Annual General Meeting of 8 May 2020, it was resolved that Iconovo shall have a Nomination Committee consisting of four members representing the four largest shareholders as of 30 September 2020.
Abbreviated interim report january-september 2020
Good progress in customer projects
